Relief Therapeutics Receives First Rranche of €2.5M Series A Funding

relief_therapeuticsRelief Therapeutics SA, a Geneva, Switzerland-based clinical stage biotechnology company, received the first tranche of a total €2.5m Series A funding round.

Global Emerging Markets made the investment. In conjunction with the funding, Peter de Svastich from GEM will join Relief’s Board of Directors.

The company intends to use the funds for clinical development activities for its lead drug candidate atexakin alfa.

Incorporated in May 2013 and led by Gaël Hédou (CEO), Michel Dreano (COO), and Yves Sagot (CSO), Relief is a clinical stage biotechnology company which develops innovative treatments aimed at providing a cure for the affections associated with degeneration of the peripheral nervous system (neuropathy). The rights to the intellectual property and its global commercialization were secured from Merck KGaA in a licensing agreement dated August 2015.




Join the discussion